Kumar, Rajiv <br/><br/>
Type I Interferons Suppress Anti-parasitic Immunity and Can Be Targeted to Improve Treatment of Visceral Leishmaniasis.  [electronic resource] 

 -  Cell reports  02 2020 
 - 2512-2525.e9 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2211-1247 
<br/><br/><label>Standard No.: </label>10.1016/j.celrep.2020.01.099  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Amphotericin B--pharmacology<br/>Animals<br/>CD4-Positive T-Lymphocytes--drug effects<br/>Cytokines--metabolism<br/>Dendritic Cells--drug effects<br/>Epitopes<br/>Humans<br/>Immunity--drug effects<br/>Inflammation--immunology<br/>Interferon Type I--pharmacology<br/>Interferon-gamma--pharmacology<br/>Leishmaniasis, Visceral--immunology<br/>Mice, Inbred C57BL<br/>Nitriles<br/>Parasites--drug effects<br/>Pyrazoles--pharmacology<br/>Pyrimidines<br/>Receptor, Interferon alpha-beta--deficiency<br/>Signal Transduction--drug effects